中国实验动物学报2026，Vol.34Issue(4)：483-495,13.DOI:10.3969/j.issn.1005-4847.2026.04.002
肾纤康通过下调COMP防治CKD-MBD大鼠的肾骨异常
Shenxiankang prevents and treats renal bone abnormalities in CKD-MBD rats by downregulating COMP
摘要
Abstract
Objective To investigate the preventive effects and potential mechanisms of Shenxiankang in chronic kidney disease-mineral and bone disorder(CKD-MBD).Methods A rat model of CKD-MBD was established.Serum creatinine(Scr)and blood urea nitrogen(BUN)were measured.Serum levels of bone alkaline phosphatase(BALP),intact parathyroid hormone(iPTH),vitamin D3(VD3),cartilage oligomeric matrix protein(COMP),fibroblast growth factor 23(FGF23),klotho,and fibroblast growth factor receptor 1(FGFR1)were determined by ELISA.Histopathological changes in renal tissues were examined using hematoxylin-eosin(HE),Masson,and picrosirius red staining.Femoral tissue morphology was assessed by HE,Masson,and tartrate-resistant acid phosphatase staining,while femoral structural parameters were evaluated using micro-computed tomography.The mRNA and protein expression levels of COMP,FGF23,klotho,and FGFR1 in renal tissues were analyzed by quantitative real-time reverse transcription PCR(RT-qPCR)and Western Blot.In addition,the expression of these molecules in renal and bone tissues was examined by immunohistochemistry.Results Compared with CKD-MBD group rats,Shenxiankang treatment significantly reduced serum creatinine,blood urea nitrogen,bone alkaline phosphatase,intact parathyroid hormone,COMP,and FGF23(P＜0.01,P＜0.05),while significantly increasing serum VD3,klotho,and FGFR1(P＜0.01).Shenxiankang also alleviated renal injury,collagen fiber deposition,and inflammatory infiltration and improved osteoporosis and bone metabolic abnormalities.Furthermore,Shenxiankang downregulated mRNA and protein expression of COMP and FGF23 in renal tissues(P＜0.01),while upregulating mRNA and protein expression of klotho and FGFR1(P＜0.01,P＜0.05).Immunohistochemical findings were consistent with these molecular result.Conclusions Shenxiankang effectively prevents and treats renal and skeletal abnormalities in CKD-MBD rats.Its therapeutic effects may be associated with downregulation of COMP and modulation of the FGF23-klotho signaling axis.关键词
肾纤康/慢性肾病-矿物质和骨代谢异常/软骨寡聚基质蛋白/FGF23-klotho轴/肾骨异常Key words
Shenxiankang/chronic kidney disease-mineral and bone disorder/cartilage oligomeric matrix protein/FGF23-klotho axis/renal bone abnormality分类
生物科学引用本文复制引用
谭碧玉,李树玲,唐伟力,杜小梅,刘建,张琼,胡琼丹..肾纤康通过下调COMP防治CKD-MBD大鼠的肾骨异常[J].中国实验动物学报,2026,34(4):483-495,13.基金项目
国家自然科学基金项目(82205002),四川省中医药管理局科技研究专项项目(2024MS524),西南医科大学科技计划项目(2023ZD008),西南医科大学中西医结合专项(2024ZXYZX02,2023ZYQJ04).Funded by National Natural Science Foundation of China(82205002),Sichuan Provincial Administration of Traditional Chinese Medicine Science Research Special Project(2024MS524),Southwest Medical University Science and Technology Planning Project(2023ZD008),Southwest Medical University Special Project on Integrated Traditional Chinese and Western Medicine(2024ZXYZX02,2023ZYQJ04). （82205002）
